Last reviewed · How we verify
Drug Therapy for Heart Failure
At a glance
| Generic name | Drug Therapy for Heart Failure |
|---|---|
| Sponsor | King's College London |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
- CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction
- Medication Withdrawal in Stable HF With Improved LVEF (PHASE2, PHASE3)
- Nurse-Led mHealth for Vulnerable-Phase Heart Failure (NA)
- Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure (NA)
- A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug Therapy for Heart Failure CI brief — competitive landscape report
- Drug Therapy for Heart Failure updates RSS · CI watch RSS
- King's College London portfolio CI